Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis

Julia Steinberg, Suzanne Hughes, Harriet Hui, Matthew J. Allsop, Sam Egger, Michael David, Michael Caruana, Peter Coxeter, Chelsea Carle, Tonia Onyeka, Isabel Rewais, Maria J. Monroy Iglesias, Nuria Vives, Feixue Wei, Derrick Bary Abila, Giulia Carreras, Marilina Santero, Emma L. O'Dowd, Gigi Lui, Musliu Adetola TolaniMaeve Mullooly, Shing Fung Lee, Rebecca Landy, Sharon J.B. Hanley, Gemma Binefa, Charlene M. McShane, Muluken Gizaw, Poongulali Selvamuthu, Houda Boukheris, Annet Nakaganda, Isil Ergin, Fabio Ynoe Moraes, Nahari Timilshina, Ashutosh Kumar, Diama B. Vale, Ana Molina-Barceló, Lisa M. Force, Denise Joan Campbell, Yuqing Wang, Fang Wan, Anna Lisa Baker, Ramnik Singh, Rehana Abdus Salam, Susan Yuill, Richa Shah, Iris Lansdorp-Vogelaar, Aasim Yusuf, Ajay Aggarwal, Raul Murillo, Julie S. Torode, Erich V. Kliewer, Freddie Bray, Kelvin K.W. Chan, Stuart Peacock, Timothy P. Hanna, Ophira Ginsburg, Mieke Van Hemelrijck, Richard Sullivan, Felipe Roitberg, André M. Ilbawi, Isabelle Soerjomataram, Karen Canfell

Producción: Contribución a una revistaArtículorevisión exhaustiva


While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I2 = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I2 = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.

Idioma originalInglés
Páginas (desde-hasta)1394-1412
Número de páginas19
PublicaciónInternational Journal of Cancer
EstadoPublicada - 15 abr. 2024


Profundice en los temas de investigación de 'Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis'. En conjunto forman una huella única.

Citar esto